Oncolytic Virotherapy for Multiple Myeloma : Past, Present, and Future

Abstract EN

Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable.

Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease.

The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, and are currently under intense clinical investigation.

Both naturally occurring and engineered DNA and RNA viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies.

Presently, only a genetically modified measles virus is in human clinical trials for MM.

The information obtained from this and other future clinical trials will guide clinical application of oncolytic viruses as anticancer agents for MM.

This paper provides a timely overview of the history of oncolytic viruses for the treatment of MM and future strategies for the optimization of viral therapy for this disease.